Neoplasma. 2018;65(2):234-241. doi: 10.4149/neo_2018_170610N420.
Early diagnosis of bladder cancer is crucial for improvement of cancer specific survival and recurrence rate. We analyzed the possible role of fluorescence urine analysis in bladder cancer diagnosis. The cohort consisted of 20 healthy controls, 40 patients with hematuria and 75 patients with hematuria and histologically proven bladder tumor. Synchronous fluores- cence spectra with a 70 nm wavelength difference were recorded for (1:1-1:128) urine dilutions. Concentration matrices of synchronous spectra (CMSS) were used to classify samples into tested groups. CMSS analysis allowed us to distinguish patients with tumor from patients with hematuria with a sensitivity 55% and specificity 74.7%. This is comparable to the sensitivity and specificity of other non-invasive tests like BTA stat and nmP-22 (Bladder check®). Lower fluorescence inten- sity of Imax 280 nm and ratio of 280 nm to 450 nm was found to be associated with the presence of tumor. We have found an association of decreased fluorescence with the stage of the disease. Our data suggest that CMSS urine analysis has a potential role in the non-invasive diagnostic tests for bladder cancer, but it cannot replace the current diagnostic algorithm yet.
早期诊断膀胱癌对于提高癌症特异性生存率和复发率至关重要。我们分析了荧光尿液分析在膀胱癌诊断中的可能作用。该队列包括 20 名健康对照者、40 名血尿患者和 75 名血尿且组织学证实为膀胱癌的患者。记录了（1:1-1:128）尿液稀释度的 70nm 波长差异的同步荧光光谱。使用同步光谱浓度矩阵（CMSS）将样本分类为测试组。CMSS 分析能够以 55%的灵敏度和 74.7%的特异性将肿瘤患者与血尿患者区分开来。这与其他非侵入性测试（如 BTA stat 和 nmP-22（Bladder check®））的灵敏度和特异性相当。发现 Imax 280nm 的荧光强度和 280nm 与 450nm 的比值降低与肿瘤的存在有关。我们发现荧光强度降低与疾病的阶段有关。我们的数据表明，CMSS 尿液分析在膀胱癌的非侵入性诊断测试中具有潜在作用，但尚不能替代当前的诊断算法。
